---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-079361"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-08-21T23:59:59+00:00"
generated_at: "2026-05-17T10:44:42.523876+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oramed shareholders approve 2M-share increase to 2019 stock incentive plan at annual meeting

## Summary
- Shareholders approved amendment to 2019 Stock Incentive Plan, increasing authorized shares by 2M to 9.5M shares.
- All seven director nominees re-elected; votes ranged from 12.5M to 13.0M for, with broker non-votes of ~6.4M.
- Auditor Kesselman & Kesselman (PwC Israel) ratified for FY2025 with 19.4M for, 1.4M against.

## SEC filing metadata
- accession: 0001213900-25-079361
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025079361/0001213900-25-079361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025079361/ea0254007-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-079361
- JSON: https://secwatch.observer/filing/0001213900-25-079361.json
- Plain text: https://secwatch.observer/filing/0001213900-25-079361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.